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Abbreviation List 
 
 
AEP        Auditory evoked potential 
CPA      Cerebellopontine angle 
CSF Cerebrospinal fluid 
CT Computed tomography  
EMG Electromyography           
fMEPs Facial nerve motor evoked 
potentials      
GR Gardner-Robertson                   
HB House-Brackmann                                 
IAC Internal auditory canal                        
IOM Intraoperative monitoring                         
LINAC Linear accelerator                         
MRI Magnetic resonance imaging       
MS Microsurgery                                  
PFO Patent foramen oval                      
RS Radiosurgery                                                      
Retrosig. Retrosigmoid Approach 
SSEPs Somato-sensory evoked potentials 
Translab. Translabrynthine Approach 
VPS Ventriculo-peritoneal shunt                 
VS Vestibular schwannoma       
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Introduction 
 
 A vestibular schwannoma (VS) is a benign tumor that 
arises from the  Schwann cells  of either the inferior (Jacob et 
al. 2007; Khrais et al. 2008) or superior (Clemis et al. 1986) 
vestibular nerve, at the neuroglial–neurilemmal junction 
(Obersteiner-Redlich zone) within the internal auditory canal 
(Thakur et al. 2012).  
Epidemiology: 
 Vestibular schwannomas make up 6-8% of all 
intracranial tumors and 70-80% of all cerebellopontine angle 
(CPA) tumors (Ojemann 1996). The annual incidence of VSs 
lies between 0.5 and 1.7 cases per 100,000, and these rates are 
increasing with the widespread use of Magnetic resonance 
imaging      (MRI), which allows for higher rates of detection 
(Myrseth et al. 2007). In a recent study, Gal et al. (2010) 
analyzed the database of the Surveillance, Epidemiology, and 
End Results program and reported that the mean age of VS 
detection in the United States is 53.1 years, and that the 
majority of lesions (84%) occur in Caucasians. In teenagers, 
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VS diagnosis is rare, and the tumor is usually associated with 
neurofibromatosis type II (NF2) (Mirzayan et al. 2007). 
Pathogenesis: 
 Vestibular schwannomas occur in two different patient 
groups; unilateral tumors occur sporadically in those with no 
family history and are not associated with other central nervous 
system tumors or abnormalities, whereas bilateral tumors occur 
in patients with NF2. In the latter, a family history usually 
exists, although occasionally a spontaneous mutation may 
occur. In some patients with NF2, other intracranial or spinal 
tumors, or both, do occur. Patients with NF2 often develop 
bilateral vestibular schwannomas, which is sufficient to make 
the diagnosis of the disease. Approximately 5 to 20% of 
patients with solitary intracranial schwannomas have NF2 
(Ojemann 1996). 
 NF2 results from germ line or somatic mutation of a 
tumor suppressor gene (NF2 gene) present on chromosome 22. 
The NF2 gene codes for a protein named separately by the two 
groups who identified it in 1993; that is, schwannomin or 
merlin (Ruttledge and Rouleau 2005).  
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Pathology: 
 Macroscopically, VSs are lobular, well-encapsulated, 
solid tumors. Consistency varies from firm to very soft, and 
adherence to surrounding structures is also quite variable 
(Sampath and Long 2004). The incidence of cystic VS in 
various studies is ranging from 7.6 to 24% of all VSs. Cystic 
VSs  can be either large single cystic region surrounded by a 
relatively small amount of peripheral tissue, single cystic 
region in a large solid tumor, or multicystic tumor (El-Bahy et 
al. 2007). Microscopically, VSs consists of two types of tissue, 
Antoni A and Antoni B fibers. Antoni B fibers are loose, 
semipalisading arrangements of Schwann cells, whereas the 
Antoni A fibers are denser, presenting more nuclei and a firmer 
cytoplasm (Sampath and Long 2004). 
Vestibular schwannomas usually grow slowly or remain 
unchanged for years or growth may progress in a stepwise 
pattern (Myrseth et al. 2007). Although there is variation in the 
literature, the results of prospective studies could be interpreted 
as suggesting that tumor growth is likely to be less than 2–2.5 
mm/year in the majority of patients. Factors that may have 
prognostic implications for VS growth patterns include: 
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significant growth (>2 mm/year), extension into the CPA, and 
tumor diameter >20 mm (Thakur et al. 2012). 
Clinical Presentation:  
 The clinical presentation of VS may vary broadly 
depending upon tumor extension; whereas intracanalicular VS 
tumors often present with high-frequency sensorineural hearing 
loss, tinnitus, vertigo, and/or dysequilibrium, extracanalicular 
tumors may also present with headache, facial hypoesthesia, 
facial weakness, ataxia, lower cranial nerve damage, or 
hydrocephalus (Moffat et al. 1993). 
 Another factor affecting clinical presentation is the site 
of origin of the tumor. Hearing is significantly better preserved 
in patients affected by medially-arising VSs than in patients 
with laterally-arising tumors (Tatagiba and Acioly 2008b). 
Furthermore, tumors that obliterate the fundus of the internal 
auditory canal (IAC) cause greater hearing loss than tumors 
that do not reach it (Somers et al. 2001). 
Radiological Findings: 
 Magnetic resonance imaging (MRI) is now the gold 
standard for vestibular schwannoma diagnosis. Tumors as 
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small as 2–3 mm may be detected using MRI (Tatagiba and 
Acioly 2008a). Most VSs have an intracanalicular component 
and often result in widening of the IAC. However, in 
a minority of cases (~20%), they are purely extracanalicular, 
only abutting the IAC (Yamakami et al. 2002). VSs are usually 
hyperintense in T2WI and slightly hypointense inT1WI. They 
may contain cystic areas and usually show intense contrast 
enhancement. Heterogeneous enhancement, cystic 
degeneration and hemorrhagic changes occur mostly in large 
tumors (Mulkens 1993). 
 Following the Hannover grading system, tumor 
extension is classified as follows: T1, purely intrameatal; T2, 
intra- and extrameatal; T3a, filling the cerebellopontine cistern; 
T3b, reaching the brainstem; T4a, compressing the brainstem; 
and T4b, severely dislocating the brainstem and compressing 
the fourth ventricle (Samii and Matthies 1997a). 
 Computed tomography (CT) of the brain can help 
identify the IAC changes (expansion or erosion) that usually 
occur with VS. CT is also helpful for planning surgery, as it 
allows one to identify the anatomy of the vestibulocochlear 
system, the position of the jugular bulb, and pneumatization of 
the temporal bone (Silk et al. 2009). 
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 The second most common type of tumor occurring in 
the cerebellopontine angle (CPA) is meningioma, which can be 
differentiated from a vestibular schwannomas by its broadly 
based dural attachment, a normal (not enlarged) IAC, 
calcification, and bony hypertrophy that occasionally narrows 
the IAC. Other tumors in the CPA include epidermoid, 
metastasis, ependymoma, and schwannomas arising from other 
cranial nerves, such as trigeminal schwannomas and lower 
cranial nerve schwannomas. However, these tumors usually 
lack the characteristic radiological findings of VSs, especially 
the changes observed in the IAC (Tatagiba and Acioly 2008a). 
Treatment: 
 Three treatment options are currently available to VS 
patients: conservative, surgical, or radiosurgical. The 
conservative treatment may be chosen for small 
intracanalicular tumors, especially in elderly patients and in 
cases where the tumor shows no significant growth 
(<2mm/year) within the first year, as monitored with MRI 
(Flint et al. 2005). 
 As a matter of fact, tumor size is a crucial factor when 
choosing the best treatment option, as it is also a major 
 
14 
 
predictor of treatment results. Large VSs represent a challenge 
to both surgical and radiosurgical treatment options. Although 
most neurotologists and neurosurgeons would agree that large 
(>3cm) tumors are best treated surgically, hearing and facial 
nerve preservation following surgery are greatest when the 
tumor is small or medium-sized (Doherty and Friedman 2006; 
Arthurs et al. 2011). 
Radiosurgery 
 In radiosurgery, ionizing radiation beams are 
stereotactically focused on an intra-cranial target volume, 
which induces biological arrest or destructive effects of the 
target area with minimal irradiation of the surrounding tissues. 
Radiosurgery can be performed with photon devices (such as 
the Gamma Knife and modified linear accelerators, LINAC) or 
with proton- and heavy-ion charged particles generated by a 
cyclotron or synchrotron (Pellet et al. 2003). 
 Relative to LINAC, Gamma Knife radiosurgery 
provides rapid treatment time per isocenter, and allows for 
simple treatment planning and relatively better field shaping 
(Chang et al. 2004). Additionally, the model C Gamma Knife 
unit (Figure 1) has an automatic positioning system that 
provides robotic control of stereotactic coordinate localization 
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in order to facilitate multiple-isocenter radiosurgery (Witham 
and Kondziolka 2004). 
 Stereotactic radiosurgery for the treatment of VS 
introduces the risk of radiation toxicity to adjacent neurologic 
structures. Therefore, this treatment option represents a 
functional threat to hearing function, balance and the integrity 
of the facial nerve. Preservation of cochlear and facial nerve 
function is the main concern during radiosurgical dose 
planning for VS. Preserving brainstem function is an additional 
concern in the case of moderate-sized and large tumors. A 
combination of small beam diameter isocenters (4- and 8-mm 
collimators) is usually used during radiosurgery for VS. Rarely, 
a 14-mm collimator is used for larger tumors. Success depends 
on high conformity to the tumor margin (Suh and Macklis 
2004). 
Better hearing preservation and less trigeminal and facial 
neuropathy have been observed after a reduction of the 
prescribed radiation doses. Currently, 13 Gy is recommended 
at the tumor margin, as this dose has been associated with 
fewer complications (Suh and Macklis 2004). 
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Figure 1: Gamma Knife Model C, the 4 mm collimator helmet 
and the automatic positioning system just before fixation of the 
patient
'
s head (Pellet et al. 2003) 
  
Adverse effects of radiation are usually observed 6-18 
months following radiosurgery, especially in cases where the 
tumor is large and the marginal dose is high. A temporary 
prescription of corticosteroids is usually sufficient to 
counteract  mild to moderate symptoms associated with 
radiation exposure; however, additional surgery may be 
required to address more severe adverse effects, such as  
neurological deterioration (Lee et al. 2010). 
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 Transient tumor swelling may occasionally occur 
following radiosurgery, which makes it difficult to adequately 
assess treatment outcome. However, if the tumor shows central 
loss of contrast enhancement, this usually indicates a positive 
response to treatment (Lee et al. 2010). 
 If radiosurgery fails and the tumor continues to grow, 
tumor removal is more difficult and at least one study has 
shown that patient outcomes are poor compared to those of 
patients who did not undergo radiosurgery (Pollock 2008).  
 A recent meta-analysis of studies evaluating the 
efficacy of Gamma Knife radiosurgery treatment of VS 
reported the following complication rates: trigeminal 
neuropathy (11-16%), facial neuropathy (4-19%), and 
hydrocephalus (2-3%) (Arthurs et al. 2011). 
Microsurgery 
 Microsurgery for VS can be performed using 
retrosigmoid, middle fossa, or translabyrinthine approaches. 
The retrosigmoid approach can be used for the removal of 
small as well as large vestibular schwannomas; in addition, it 
allows for hearing preservation surgery (Sampath and Long 
2004). Complete tumor removal is usually possible with the 
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retrosigmoid approach, and the endoscope can be used to 
remove the portion of the tumor extending laterally into the 
IAC (Doherty and Friedman 2006). 
 Surgical removal of VS with the retrosigmoid approach 
can be performed with the patient in a supine, park-bench, or 
semi-sitting position. The semi-sitting position has the 
advantage of spontaneous drainage of the cerebrospinal fluid 
(CSF) and blood, which provides a clean surgical field, thereby 
reducing the dissection time and reducing the risk of damage to 
cranial nerves. Possible  complications associated with the 
semi-sitting position may be minimized  by  doing the 
following: monitoring of somato-sensory evoked potentials 
(SSEPs) during patient positioning, performing intraoperative 
trans-esophageal echocardiography, and applying a central 
venous catheter with the tip positioned close to the superior 
vena cava-right atrium junction, to allow for premature 
detection of air embolisms (Porter et al. 1999). Even patients 
with a patent foramen oval (PFO) can be operated safely in the 
semi-sitting position under standardized anaesthesiological and 
neurosurgical protocols (Feigel et al. 2014). 
 Routine use of intraoperative auditory and facial nerve 
monitoring have been shown to result in increased rates of 
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hearing and facial nerve preservation. The auditory evoked 
potential (AEP) is the most widely used method for monitoring 
auditory function intraoperatively. Intraoperative facial nerve 
monitoring can be performed using direct electrical 
stimulation, continuous electromyography (EMG), and facial 
nerve motor evoked potentials (fMEPs) (Tatagiba and Acioly 
2008b). 
 Although total tumor removal should be the aim in VS 
surgery, near-total removal is also accepted when a thin layer 
of tumor is intentionally left attached to one or more nerves or 
to the brainstem surface in an attempt to preserve neurological 
function. Long-term rates of tumor control do not differ 
significantly between cases of gross-total resection and cases in 
which a small amount of tumor is left behind (Sughrue et al. 
2011). 
 An enlargement of the residual tumor or the IAC or 
CPA cisternal space observed during follow-up imaging may 
indicate tumor recurrence. Recurrent tumors should be treated 
with radiosurgery whenever possible, as repeat surgery is more 
difficult; repeat surgery becomes necessary in the case of large 
recurrent tumors or when radiosurgery has failed (Sughrue et 
al. 2011). 
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Studies comparing Microsurgery and Radiosurgery 
 To the best of our knowledge, there are currently no 
randomized clinical trials on vestibular schwannomas (VS). 
Only two prospective controlled studies with predefined 
inclusion criteria compared microsurgery (MS) to radiosurgery 
(RS) for the treatment of VS (Pollock et al. 2006 and Myrseth 
et al. 2009). There are also four retrospective cohort studies 
with a matched control group, all comparing microsurgery with 
radiosurgery (Pollock et al. 1995, Karpinos et al. 2002, Régis et 
al. 2002, Myrseth et al. 2005). The patient selection criteria and 
results of these studies are summarized in Table 1. 
 Four of these studies (Pollock et al. 2006 and Myrseth 
et al. 2009, Pollock et al. 1995, Myrseth et al. 2005) included 
only tumors smaller than 30 mm. The study by Karpinos et al. 
included large and small tumors as well as recurrent tumors. 
Régis et al. classified tumor size based on the Koos grading 
system and included only stage II and III in the comparison. 
 Although results following microsurgery may differ 
based on the surgical approach used, these comparative studies 
included different surgical approaches in their microsurgery 
groups. In addition, some of these studies did not mention the 
type of intraoperative neurophysiological monitoring used 
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(Pollock et al. 2006), while others did not perform 
intraoperative auditory monitoring (Régis et al. 2002, Myrseth 
et al. 2005, Myrseth et al. 2009).    
 Due to a lack of long-term follow-ups, some of these 
studies did not report tumor control outcomes (Pollock et al. 
2006, Myrseth et al. 2009). In their study, Régis et al. 
commented on treatment failure in the context of retreatment 
rate, and their results showed a failure rate of 3% in the 
radiosurgery group (with follow-up of 3 years) and 5% in the 
surgery group (follow-up of 5 years). 
 The relatively small patient groups and short follow-up 
periods are potential weaknesses of some of these comparison 
studies (Wolbers et al. 2013). 
 In the current manuscript, we present a retrospective 
study comparing long-term results after microsurgery and 
radiosurgery for vestibular schwannomas. The tumors were 
classified according to the Hannover Classification system, and 
we compared comparable tumor extension grades in 
microsurgery and radiosurgery. Our study included 269 
patients in the microsurgery group and 427 patients in the 
radiosurgery group, and the mean follow-up time was 16.4 ad 
42.4 months, respectively. We also present the tumor control 
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results for a subgroup of the radiosurgery group who received 
follow-up of more than 2 years. All patients in both groups 
received the same standards of treatment. In the microsurgery 
group, all patients received the retrosigmoid approach in the 
semi-sitting position and IOM of the facial and auditory 
nerves; in the radiosurgery group, on the other hand, all 
patients received Gamma Knife radiosurgery with mean tumor 
margin dose of 13 Gy and mean maximum dose of 21 Gy. 
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Table 1: Checklist on cohort studies comparing microsurgery 
(MS) and radiosurgery (RS) for solitary vestibular schwannoma 
Authors & 
Publication 
year 
Pollock 
 2006 
Myrseth 
2009 
Pollock  
1995 
Myrseth 
2005 
Regis 
 2002 
Kaprinos 
2000 
Study Design 
 
Prospecti- 
ve 
 
Prospecti--
ve 
 
Retrospec-
tive 
 
Retrospec-
tive 
 
Retrospec-
tive 
 
Retrospecti-
ve 
 
No. of Patients 
     MS 
     RS 
 
 
36 
46 
 
 
28 
60 
 
 
40 
47 
 
 
 
86 
103 
 
 
110 
97 
 
 
23 
49 
Inclusion 
Criteria 
  Recurrent 
  Size 
 
 
No 
<  3 cm 
 
 
 
No 
<  3 cm 
 
 
 
No 
< 3cm 
 
 
 
No 
< 3 cm 
 
 
 
No 
Koos 
stage II, 
III 
 
 
Yes 
All sizes 
Follow-up 
(mean  in 
months) 
42  24 36 69 36 MS 24 
RS 48 
Surgery 
  Approach 
     
 
 
 
 
  
  IOM: 
      Facial 
      
     
 Hearing 
 
 
 
Retrosig. 
(25) 
Translab. 
(9) 
Middle 
fossa (2) 
 
 
Not 
indicated 
 
Not 
indicated 
 
 
Retrosig. 
(27) 
Translab. 
(1) 
 
 
 
 
Used 
 
 
Not used 
 
 
 
Translab. 
Retrosig.  
(number 
not 
indicated 
 
 
 
Not 
indicated 
 
Not 
indicated 
 
 
Translab.
.Retrosig. 
(number 
not 
indicated 
 
 
 
Used 
 
 
Not used 
 
 
 
Translab. 
(85%) 
Middle 
Fossa 
(15%) 
 
 
 
Not 
indicated 
 
Not used 
 
 
 
Translab. 
(15) 
Retrosig. 
(7) 
Middle 
Fossa(1) 
 
 
Used 
 
 
Used 
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Radiosurgery 
   
 Marginal dose  
  
Gamma 
Knife 
 
Mean 12 
Gy 
 
Gamma 
Knife 
 
Not 
indicated 
Gamma 
Knife 
 
Not 
indicated 
Gamma 
Knife 
 
10-12 Gy 
 
Gamma 
Knife 
 
12-14 Gy 
Gamma 
Knife 
 
14.5 Gy 
Facial 
preservation 
(%) 
     MS 
     RS 
 
 
 
83 
98 
 
 
 
82 
100 
 
 
 
78 
91 
 
 
 
80 
95 
 
 
 
67 
100 
 
 
 
64.7 
93.9 
Hearing 
preservation 
(%) 
     MS 
     RS 
 
 
 
5 
63 
 
 
 
0 
68 
 
 
 
14 
75 
 
 
 
5 
32 
 
 
 
36 
50 
 
 
 
40 
44 
Tumor 
Control 
Not 
included 
Not 
included 
Not 
included 
94.2% 
(MS) 
89.2% 
(RS) 
Retreat-
ment  
MS (9%) 
RS (3%) 
100% (MS) 
91%(RS) 
Vertigo or 
Imbalance 
Radiosur. 
better 
No diff. No diff. Not 
included 
Radiosur.
better 
No diff. 
Tinnitus No diff. No diff. No diff. Not 
included 
No diff. 26.5% 
worsening 
(RS) 
0% 
worsening 
(MS) 
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Objectives 
 
 In the present study, we aimed to compare the long-
term treatment results of patients harboring VSs who had been 
previously submitted to either radiosurgical or microsurgical 
treatment. We paid special attention to i) resection radicality 
based on volumetric studies, ii) tumor recurrence, iii) 
preservation of facial nerve function, iv) hearing preservation, 
v) preservation of trigeminal nerve function, and vi) 
improvement in tinnitus and dizziness. 
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Patients and Methods 
 
 We conducted a retrospective study with two groups of 
patients who were treated for vestibular schwannoma (VS). 
Patients in the first group were treated with surgery between 
2004 and 2010 in the Neurosurgery Department  of Tübingen 
University (Tübingen, Germany), and patients in the second 
group were treated with radiosurgery between 1997 and 2010 
at the Krefeld Gamma Knife Center in Krefeld, Germany.  
Inclusion criteria 
Inclusion criteria were as follows: 
1. no previous treatment, either surgical or radiosurgical 
2. absence of neurofibromatosis 
Exclusion criteria 
 previously treated patients 
 Neurofibromatosis type 2 (NFII) 
 Follow-up period shorter than 6 months 
 The following data were obtained from all patients: 
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 Symptomatology (prior to treatment). 
 Neurological examination, with special emphasis on cranial 
nerves V-XII. 
 Clinical assessment of facial nerve function using the House-
Brackmann grading scale (Table 2). 
 Audiological evaluation using pure-tone audiogram; pure tone 
average and speech discrimination percentage was assessed 
using the Gardner-Robertson grading scale (Table 3). 
 Outcome after treatment, including: 
- Tumor control 
- Facial nerve function (House-Brackmann scale) 
- Hearing function (Gardner-Robertson scale) 
- New symptoms 
- Other complications 
Surgical technique 
 Microsurgical resection was performed by single 
neurosurgeon (Prof. M. Tatagiba) using the retrosigmoid 
approach in the semi-sitting position. Intraoperative 
neurophysiological monitoring of hearing function (Brainstem 
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auditory evoked potential) and facial function (facial motor 
evoked potential “fMEP”, direct nerve stimulation and free 
running electromyography “EMG”) were used in all cases. 
 
Table 2: House-Brackmann facial nerve grading scale (House and 
Brackmann 1985) 
Grade Description 
I Normal facial function in all muscles 
II Slight weakness noticeable only on close inspection, complete eye closure 
III 
Obvious but not disfiguring difference between two sides; forehead shows 
slight-to-moderate movement; complete eye closure with effort 
IV 
Obvious weakness, disfiguring asymmetry; no forehead movement; 
incomplete eye closure 
V Barely perceptible motion 
VI Total paralysis 
 
Radiosurgical technique 
 Radiosurgery was performed with a 201-source cobalt-
60 Leksell Model U Gamma Knife (Elekta Instruments). MRI 
high-resolution, T2 and gadolinium-enhanced, T1-weighted 
images were obtained to localize the area of interest. Dose 
planning enclosed the tumor contour within 65% isodose line 
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in most of the cases and the average marginal dose was 13 Gy 
(Table 4). 
Table 3: Gardner-Robertson grading of hearing function 
(Gardner and Robertson 1988) 
 
Table 4: Radiosurgery parameters 
Radiation treatment 
parameter 
Range Average 
Central tumor dose 20-28.3 Gy 21 Gy 
Tumor margin dose 12-13 Gy 13 Gy 
Isocenter No. 3-50 23.3 
Isodose line 50-65% 63% 
 Grade Description Pure 
tone average 
(dB) 
Speech 
discrimination score (%) 
I Good to excellent 0-30 70-100 
II Serviceable 31-50 50-69 
III Non-serviceable 51-90 5-49 
IV Poor 91-100 1-4 
V None Not testable 0 
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Statistical analysis 
        Analyses were conducted using SPSS software 
(Version 17; SPSS, Inc., Chocago, IL). We generated a 
histogram to assess data distribution. Continuous variables are 
expressed as mean +/- standard deviation (SD), and were 
analyzed using paired or unpaired Student t tests or ANOVA. 
All statistical tests were two-tailed. The association between 
variables was analyzed using the Pearson correlation 
coefficient. Nonparametric equivalents, i.e. the Mann-Whitney 
U-test, Wilcoxon-signed ranks test and Spearmann ranked 
correlation coefficient were used for nonparametric data. 
Statistical significance was set at p < 0.05. 
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Results 
Patient data 
 The surgery group included 269 cases (122 males and 
147 females) ranging in age from 20.9 to 75.2 years (mean age 
= 47.8 years). The radiosurgery group, on the other hand, 
included 427 cases (168 males and 259 females) ranging in age 
from 20 to 85 years (mean age = 58.1 years).  
 Tumor extension in the two groups, as assessed with the 
Hannover grading scale, is shown in Table 5, Figure 2.  
Groups did not differ from each other in terms of gender 
(p=0.08), facial nerve function (p=0.112) or incidence of 
tinnitus (p=0.076). Tumor size, however, was significantly 
larger in the surgery group, which reflects the criteria used for 
treatment indication (p<0.001). Hearing (p<0.01), vestibular 
nerve (p<0.01) and trigeminal nerve functions (p<0.001) were 
also significantly more compromised in the surgery group (as a 
direct consequence of tumor size).  
Clinical complaints 
In the surgery group, 209 patients (77.6%) reported 
tinnitus, 182 patients (67.7%) reported dizziness, and 36 
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patients (13.4%) reported facial hypoesthesia before surgery. In 
the radiosurgery group, on the other hand, 238 patients (55.7%) 
reported tinnitus, 307 patients (71.9%) reported dizziness, and 
45 patients (10.5%) reported facial hypoesthesia before 
treatment (Table 6). 
Facial nerve function before treatment 
Twenty-one patients (7.8%) in the surgery group had 
compromised facial nerve function prior to treatment, while the 
same was true for 15 patients (3.5%) in the radiosurgery group. 
Table 7 shows motor facial function in both groups, as assessed 
with the House-Brackmann (HB) grading scale. Facial nerve 
function before treatment did not differ significantly between 
both treatment groups (P value = 0.112, Spearman's rho 
correlation). 
Hearing function before treatment 
One-hundred fifty five patients (57.6%) in the surgery 
group and 226 patients (52.9%) in the radiosurgery group had 
non-functional hearing (higher than grade II on the Gardner-
Robertson scale) before treatment. Table 8 shows the Gardner-
Robertson hearing scores before treatment for both groups. 
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Hearing was significantly compromised in the surgery group (P 
value < 0.01, Spearman's rho correlation). 
 
Table 5: Demographic data in both groups 
Variable Surgery group Radiosurgery 
group 
P Value 
Total number 269 427  
Age in years 
              Range 
              Mean 
 
20.9 - 75.2 
47.8 
 
20 - 85 
58.1 
 
 
0.216 
Sex 
             Female 
             Male 
 
147 
122 
 
259 
168 
0.08 
Tumor Extension 
            T1 
            T2 
            T3a&b 
            T4a&b 
 
21 
69 
103 
76 
 
58 
137 
164 
68 
<0.001 
 
34 
 
 
Figure 2: Tumor extension in both groups (presented in percentages) 
 
Table 6: Symptoms and signs before treatment 
Finding 
before 
Treatm
ent 
Surgery Group Radiosurgery Group P- 
Valu
e 
T
1 
T
2 
T3a
&b 
T4a
&b 
Tot
al 
T
1 
T2 T3a
&b 
T4a
&b 
Tot
al 
 
Dizzine
ss 
1
4 
4
3 
67 58 182 2
8 
79 93 38 238 <0.0
1 
Tinnitu
s 
1
6 
5
2 
76 65 209 4
3 
10
1 
118 45 307 0.07
6 
Facial 
Hypoth
. 
2 4 6 24 36 1 6 15 23 45 <0.0
01 
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Table 7: Facial nerve function before treatment 
House- 
Brackm
ann 
grade 
Surgery Group Radiosurgery Group P- 
Val
ue 
T
1 
T
2 
T3a
&b 
T4a
&b 
Tot
al 
T
1 
T
2 
T3a
&b 
T4a
&b 
Tot
al 
 
0.11
2 I 2
1 
6
7 
97 64 248 5
8 
13
5 
157 62 412 
II 0 2 6 12 20 0 0 2 1 3 
III 0 0 1 0 1 0 2 1 2 5 
VI 0 0 0 0 0 0 0 2 1 3 
V 0 0 0 0 0 0 0 2 2 4 
Total 2
1 
6
9 
103 76 269 5
8 
13
7 
164 68 427 
 
 
 
 
 
 
 
 
 
36 
 
Table 8: Hearing function before treatment 
Gardne
r 
Robert
son 
Surgery Group Radiosurgery Group P 
Val
ue 
T
1 
T
2 
T3a
&b 
T4a
&b 
Tot
al 
T
1 
T2 T3a
&b 
T4a
&b 
Tot
al 
 
 
<0.0
1 
I 5 6 8 1 20 1
4 
21 26 8 69 
II 1
0 
2
8 
38 18 94 2
0 
49 48 15 132 
III 6 3
0 
49 38 123 2
1 
54 68 20 163 
VI 0 2 5 9 16 2 7 15 17 41 
V 0 3 3 10 16 1 6 7 8 22 
Total 2
1 
6
9 
103 76 269 5
8 
13
7 
164 68 427 
 
Treatment results 
The follow-up period for the surgery group ranged from 
6 to 74 months (mean = 16.4 months), while for the 
radiosurgery group, it ranged from 7 to 144 months (mean = 
42.4 months). 
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Tumor control 
Tumor volume in the radiosurgery group was measured 
at follow-up and compared to tumor volume before treatment; 
it was then classified into 3 categories: shrinkage, expansion or 
stable. Shrinkage was defined as a greater than 10% decrease 
in tumor volume, tumor expansion as a greater than 10% 
increase in tumor volume, and ‘stable’ was when a tumor 
increased or decreased in size by less than 10% relative to its 
pre-treatment volume. 
Tumor volumetric assessment 6 months after treatment 
revealed tumor expansion in 148 patients (34.7%), stable tumor 
size in 177 patients (41.5%), and tumor shrinkage in 102 
patients (23.9%). Three patients (0.7%) required urgent 
intervention in the form of a ventriculo-peritoneal shunt (VPS) 
as a result of tumor expansion and the development of 
hydrocephalus after radiosurgery. VPS insertion was 
performed 3 weeks after radiosurgery in one case, and 6 and 18 
months after radiosurgery in the other 2 cases.  
At the time of the last follow-up, however, 58 patients 
(13.6%) had experienced tumor expansion, 62 patients (14.5%) 
had tumors that remained stable, and 307 patients (71.9%) had 
experienced tumor shrinkage (Table 9, Figures 3 and 4). 
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The follow-up period in the radiosurgery group ranged 
between 7 and 144 months (mean = 42.4 months). There was a 
significant correlation between tumor control and time post-
treatment (P value< 0.001, Pearson Correlation), so that the 
mean follow-up period in cases of tumor shrinkage was 49.2 
months; however, in cases of stable tumors and tumor swelling, 
the mean follow-up period was 19 and 20.8 months, 
respectively.  
No significant correlation was found between tumor 
control and tumor extension (Table 10). 
 
Table 9: Tumor control in the radiosurgery group 
  Tumor control at last follow-up 
Total   Shrinkage Stable Expansion 
Tumor control at 6 
months 
Shrinkage 96 2 4 102 
Stable 129 37 11 177 
Expansion 82 23 43 148 
Total 307 62 58 427 
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Figure 3: Tumor control in the radiosurgery group 
 
 
Table 10: Tumor control at the last follow up in relation to 
tumor extension  
 T1 T2 T3a&b T4a&b 
Shrinkage 41 (70.7%) 95 (69.3%) 122 (74.4%) 49 (72.1%) 
Stable 11 (19%) 18 (13.1%) 20 (12.2%) 13 (19.1%) 
Expansion 6 (10.3%) 24 (17.5%) 22 (13.4%) 6 (8.8%) 
Total 58 137 164 68 
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           Treatment 2.4 cm3                                          6 months follow up 2.9 cm3   
 
        18 months follow up 0.9 cm3                            30 months follow up 0.6 cm3      
 
Figure 4: Sequential follow-up MR images showing transient early 
postradiosurgery tumor swelling of right Class T3a VS 
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Additionally, we were able to obtain long-term results 
for 339 patients who were followed for more than 2 years. 
From this group, 253 patients (74.6%) displayed tumor 
shrinkage, 42 patients (12.4%) had tumors that remained 
stable, and 44 patients (13%) experienced tumor swelling. 
In the surgery group, total tumor removal was 
performed in 263 patients; in the remaining 6 cases (Table 11); 
a small part of the tumor was left in order to preserve the 
integrity of the facial nerve. After a mean follow up of 16.4 
months, excellent tumor control with no tumor recurrence or 
increase in size of the residual tumor occurred in 268 patients 
(99.6%). In one patient (0.37%), tumor size had increased at 
follow-up, and then the residual tumor was treated by 
radiosurgery. 
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Figure 5: Magnetic resonance imaging preoperative (left) and 17 
months postoperative (right) of T4a VS showing complete tumor 
removal with no recurrence 
 
Table 11: Cases of incomplete tumor removal (surgery group) 
Case Nr. Tumor 
Extension 
Patient Age at 
treatment 
(years) 
Period of 
follow-up 
(months) 
Increased 
residual size 
1 T2 49 17 No 
2 T3b 55 15 No 
3 T3b 51 17 No 
4 T4a 49 35 No 
5 T4a 35 74 No 
6 T4a 75 40 Increased 
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Results related to the hearing function 
In the surgery group, 114 patients (42.4%) had 
preoperative functional hearing (Gardner-Robertson grades I or 
II), from these patients 67 patients (58.8%) had functional 
hearing at the last follow-up. Hearing preservation was found 
to be significantly correlated with tumor extension in the 
surgery group (P value < 0.001, Spearman's rho correlation) 
(Table 12, 13).  
In the radiosurgery group, 201 patients (47.1%) had 
serviceable hearing before treatment. Of these, 132 patients 
(65.7%) had functional hearing at the last follow-up. As was 
seen in the surgery group, hearing preservation was 
significantly correlated with tumor extension in the 
radiosurgery group (P value = 0.006, Spearman's rho 
correlation) (Table 12, 13).   
Importantly, 2 patients (1.1%) in the surgery group and 
7 patients (2.5%) in the radiosurgery group had functional 
hearing after treatment, even though they did not have 
functional hearing before treatment. 
At the time of the last follow-up, hearing was found to 
be significantly better-preserved in the radiosurgery group (P 
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value < 0.001, Mann-Whitney). As shown in table 13, the 
results hearing preservation in small tumors (Class T1, T2 and 
T3) were comparable between surgery and radiosurgery.  
 
Table 12: Hearing after treatment (at last follow-up) in cases of 
serviceable hearing before treatment 
Gardner 
Robertso
n 
Surgery Group Radiosurgery Group 
T
1 
T
2 
T3a&
b 
T4a&
b 
Tota
l 
T
1 
T
2 
T3a&
b 
T4a&
b 
Tota
l 
I 3 2 1 0 6 1
2 
1
2 
23 8 55 
II 1
0 
1
9 
27 5 61 1
3 
2
7 
29 8 77 
III 1 5 11 6 23 9 2
8 
20 6 63 
VI 0 0 2 1 3 0 3 2 1 6 
V 1 8 5 7 21 0 0 0 0 0 
Total 1
5 
3
4 
46 19 114 3
4 
7
0 
74 23 201 
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Figure 6: Hearing preservation in both groups 
 
 
Table 13: Hearing preservation rate (GR grade I or II) in patients 
having functional hearing before treatment 
 
 
Tumor Extension 
Hearing preservation rate (%) 
Surgery group Radiosurgery 
group 
T1 86.7 73.5 
T2 61.8 55.7 
T3a&b 60.9 70.3 
T4a&b 26.3 69.6 
Total 58.8 65.7 
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Facial nerve results 
The facial nerve was anatomically preserved in 265 
patients (98.5%) in the surgery group. A total of 251 patients 
(93.3%) had House-Brackmann (HB) grade I or II facial 
function at the last follow-up, and a significant correlation was 
found between facial function preservation and tumor 
extension (P value < 0.0001, Spearman's rho correlation) 
(Table 14 and 15, Figure 7). 
In the radiosurgery group, on the other hand, 416 
patients (97.4%) had HB grade I or II facial function at the last 
follow-up after treatment, and no significant correlation was 
found between facial function preservation and tumor 
extension (P value = 0.502, Spearman's rho correlation) (Table 
14 and 15,  Figure 7).      
Facial function at the last follow-up was found to be 
significantly better in the radiosurgery group (P value < 0.001, 
Mann-Whitney).  
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Table 14: Facial function at last follow up 
House- 
Brackma
nn grade 
Surgery Group Radiosurgery Group 
T
1 
T
2 
T3a&
b 
T4a&
b 
Tot
al 
T
1 
T2 T3a&
b 
T4a&
b 
Tot
al 
I 2
1 
6
0 
81 42 204 5
6 
13
5 
157 63 411 
II 0 7 19 21 47 1 0 3 1 5 
III 0 2 2 9 13 0 1 1 1 3 
VI 0 0 1 3 4 0 0 1 3 4 
V 0 0 0 1 1 1 1 2 0 4 
Total 2
1 
6
9 
103 76 269 5
8 
13
7 
164 67 427 
 
 
Figure 7: Facial function preservation at last follow-up 
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Table 15: Facial nerve function preservation rate (HB grade I or II) 
at the last     follow up 
 
Tumor Extension 
Facial function preservation rate 
(%) 
Surgery group Radiosurgery 
group 
T1 100 98.3 
T2 97.1 98.5 
T3a&b 97.1 98.2 
T4a&b 82.9 95.5 
Total 93.3 97.4 
 
 
Other symptoms: 
The presence or absence of other symptoms as well as 
symptom severity was compared before and after treatment in 
both groups. 
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Table 16: Results of dizziness, tinnitus, and trigeminal nerve 
function after treatment in both groups 
 
 Patients who had dizziness before 
treatment    
New 
dizziness 
P 
Value 
 cured improve Same worse 
Surgery 128 
(70.3%) 
36 
(19.8%) 
15 
(8.2%) 
3 (1.6%) 21 (7.8%) <0.0001 
Radiosurgery 85 
(36%) 
25 
(10.6%) 
105 
(44.4%) 
21 
(8.9%) 
35 (8.2%)  
 Patients who had tinnitus before 
treatment    
New 
tinnitus 
P 
Value 
 cured improve Same worse 
Surgery 173 
(82.2%) 
7 (3.3%)  24 
(11.5%) 
5 (2.4%) 35(1.9%) <0.0001 
Radiosurgery 38 
(12.3%) 
32 
(10.4%) 
217 
(70.2%) 
22(7.1%) 25 (5.9%) 
 Patients who had trigeminal nerve 
dysfunction before treatment    
New 
trigeminal 
dysfunction 
P 
Value 
 cured improve Same worse 
Surgery 35 
(97.2%) 
0 1 
(2.8%) 
0 4 (1.5%) =0.036 
Radiosurgery 25 
(55.6%) 
6 
(13.3%) 
13 
(28.9%) 
1 (2.2%) 14 (3.3%) 
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Results related to dizziness 
In patients who complained of dizziness prior to 
surgery, 90.1% improved either completely or partially after 
treatment. Another 8.2% reported that their dizziness had 
remained unchanged, and an additional 7.8% developed new 
dizziness after surgery. 
Among the radiosurgery patients who reported 
dizziness prior to surgery, 44.5% reported persistent dizziness 
following treatment, 46.6% reported improvement, 8.9% 
reported worsening of dizziness, and 8.2% reported developing 
new dizziness after radiosurgery. 
The outcome related to dizziness was significantly 
more favorable in the surgery group (P value < 0.0001, Mann-
Whitney). 
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Figure 8: Dizziness results at the last follow-up in both groups 
 
Results related to Tinnitus 
In patients who complained of tinnitus prior to surgery, 
85.5% improved either completely or partially after treatment. 
Another 11.5% reported that their tinnitus had remained 
unchanged, and an additional 2.4% developed new tinnitus 
after surgery. 
Among the radiosurgery patients who reported tinnitus 
prior to treatment, 760.2% reported persistent tinnitus 
following treatment and 22.7% reported improvement, 
however, 5.9% reported developing new tinnitus after 
radiosurgery. 
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The outcome related to tinnitus was significantly more 
favorable in the surgery group (P value < 0.0001, Mann-
Whitney). 
 
 
Figure 9: Tinnitus results at the last follow-up in both groups 
 
Results related to trigeminal nerve function 
In the surgery group, 36 patients experienced trigeminal 
nerve dysfunction in the form of hypoesthesia and/or 
dysesthesia before treatment, and 35 of these patients improved 
completely after treatment (97.2%). In the radiosurgery group, 
on the other hand, 45 patients had trigeminal nerve dysfunction 
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before treatment, and 31 patients (68.9%) improved after 
treatment.  
 
 
Figure 10: Trigeminal results at the last follow-up in both groups 
 
Small versus large tumors 
 Since tumor size influences the choice of treatment, 
tumors in patients in the surgery group were consistently 
larger. Therefore, we further analyzed patients by stratifying 
them into small and large tumor groups. Following the 
Hannover classification for vestibular schwannomas, small 
tumors in our group were classified as grades T1 and T2, 
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whereas large tumors were classified as grades T3a, T3b, T4a 
and T4b. 
 The two small tumor groups (radiosurgery and surgery) 
did not differ significantly from each other in terms of gender 
(p=0.082, Chi square), size stratification according to the 
Hannover classification (p=0.305, Mann Whitney U), facial 
nerve function (p=0.195, Mann Whitney U) and hearing 
function (p=0.925, Mann Whitney U), incidence of tinnitus 
(p=0.065, Chi square), and trigeminal symptoms (p=0.266, Chi 
square); however, the groups differed in terms of age (p<0.001, 
Mann Whitney U) and incidence of dizziness (p<0.05, Chi 
square).  
 The two large tumor groups (radiosurgery and surgery), 
on the other hand, did not differ significantly from each other 
regarding gender (p=0.576, Chi square), facial nerve (p=0.066, 
Mann Whitney U), hearing function (p=0.355, Mann Whitney 
U), incidence of tinnitus (p=0.544, Chi square), dizziness 
(p=0.138, Chi square), or trigeminal symptoms (p=0.372, Chi 
square). However, they did differ from each other regarding 
age (p<0.001, Mann Whitney U) and tumor size (p<0.01, Mann 
Whitney U, i.e., larger in the surgery group). 
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 In terms of final tumor volume (relative to pre-
treatment size), surgery proved to be superior to radiosurgery 
for both small and large tumors (p<0.001 in both, Mann 
Whitney U). Nevertheless, radiosurgery was better than 
surgery in preserving facial nerve and hearing functions in 
large tumors; however in small tumors the results were 
comparable between surgery and radiosurgery. We also 
observed a relative advantage of surgery over radiosurgery for 
tinnitus, dizziness and facial hypoesthesia in the case of small 
tumors only (p<0.001 for both dizziness and facial 
hypoesthesia, Chi square). For facial hypoesthesia, the 
difference between treatments practically disappeared with 
regard to large tumors.  
 
Complications 
  Five patients (1.2%) in the radiosurgery group 
developed hydrocephalus after treatment. Another eight 
patients (1.9%) developed trigeminal neuralgia, with transient 
pain in two patients and permanent pain in six patients. The 
most common complication after radiosurgery was facial 
spasm, which occurred in 16 patients (3.7%). 
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   The most common complication after surgery was 
cerebrospinal fluid (CSF) rhinorrhea, which occurred in 24 
patients (8.9%). The leakage stopped after lumbar drainage in 
21 patients, while wound revision was indicated in three cases. 
Five patients (2.7%) developed trigeminal hypoesthesia. Four 
patients (1.5%) developed delayed postoperative 
hydrocephalus and ventriculo-peritoneal shunting was 
indicated. Two patients (0.7%) developed bilateral frontal 
pneumocephalus, which was treated with burr hole drainage. 
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Discussion 
 
Vestibular schwannoma (VS) has a slightly higher 
incidence in women (Mirzayan et al. 2007). In the present 
work, the male to female ratio was 1:1.17 in the surgery group 
and 2:3 in the radiosurgery group. A possible explanation for 
the larger number of female patients in the radiosurgery group 
is that females may be more likely than males to choose the 
radiation option. 
Several authors have reported that the typical age for 
VS diagnosis is during the fifth to sixth decades of life, while 
patients with NF2 are usually younger (Samii et al. 2006, 
Myrseth et al. 2007; Tatagiba & Acioly 2008b). A few series 
studies comparing microsurgery and radiosurgery for treating 
VS documented a significantly higher average age among 
radiosurgery patients (Pollock et al. 2006, Myrseth et al. 2005, 
Karpinos et al. 2000, Regis et al. 2002, Pollock et al. 1995). 
The mean age in our groups was 47.8 in the surgery group and 
58.1 in the radiosurgery group, which did not differ 
significantly.    
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Hearing loss and/or tinnitus are the most common 
complaints in VS patients, followed by dizziness and/or 
imbalance due to vestibular nerve dysfunction. Other 
complaints may be related to trigeminal or facial nerve 
dysfunction, and lower cranial nerve dysfunction may also 
occur with large VSs (Matthies and Samii 1997b; Myrseth et 
al. 2007). The rates of trigeminal nerve dysfunction, facial 
nerve dysfunction, and hearing loss in this series were 
significantly higher among patients who had tumors that 
extended more into the cerebellopontine cistern (P value < 
0.001). However, tinnitus and dizziness were not related to 
tumor extension. In addition, both surgery and radiosurgery 
groups were matched regarding symptomatology prior to 
treatment. 
The treatment options available to VS patients include 
observation, surgery or radiosurgery. A more conservative 
treatment option may be offered to a patient with a small or 
medium-sized tumor, especially when the patient is elderly or 
suffers from additional medical problems; however, it should 
be noted that conservative management is not without risk, as 
hearing loss or disabling symptoms may occur as a result of 
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increasing tumor size (Lin et al. 2005; Doherty and Friedman 
2006). 
 There is some disagreement over the best treatment 
option for VS, especially when it comes to medium-sized 
tumors; however, it is commonly believed that VSs causing 
brainstem compression as well as cystic VSs should be  treated 
surgically (Charabi et al. 2000). 
 Although randomized clinical trials represent the gold 
standard of evidence-based practice, it may be not possible to 
randomize patients between microsurgery and radiosurgery. 
Next best evidence is obtained from well-designed non-
randomised controlled trials (Vandenbroucke 2004). The 
present study presents a retrospective long-term comparative 
analysis of VS treatment in a large number of VS patients from 
two different specialized centers. Patients were informed about 
the expected results and possible complications of both surgery 
and radiosurgery before they chose a treatment option.  
As mentioned above, six observational studies have 
been published comparing microsurgery and radiosurgery for 
the treatment of VS (Pollock et al. 1995, Karpinos et al. 2002, 
Régis et al. 2002, Myrseth et al. 2005, Pollock et al. 2006, 
Myrseth et al. 2009). Except for the study by Karpinos et al. all 
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studies excluded cases of recurrent tumors as well as tumors 
larger than 3 cm in diameter.  
We used the Hannover classification of tumor extension 
in our comparative study for two reasons: 1) it was the 
classification system used by the 2 centers from which we 
collected our data, and 2) tumor extension and its relation to 
important adjacent structures in the cerebellopontine angle may 
have more impact on the treatment results than tumor size 
alone.  
Régis et al. classified tumors according to the Koos 
grading system and included only grade II and III tumors in 
their comparison. They excluded grade I and IV tumors from 
the comparison in order to avoid comparing large tumors 
treated by microsurgery with small tumors treated by 
radiosurgery.  
The large number of cases included in our series 
allowed us to compare different comparable grades of tumor 
extension in the microsurgery and radiosurgery groups.  
Three different approaches may be used for the surgical 
resection of VS: retrosigmoid, middle fossa and 
translabyrinthine. The risks can be minimized and the results 
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can be maximized if the operating team uses the surgical 
approach they are most familiar with (Matthies and Samii 
1997a). The translabyrinthine approach cannot be used if 
hearing preservation is attempted; the middle fossa approach is 
recommended for small tumors. The retrosigmoid approach, 
instead, can be used for the removal of both large and small 
VSs, while preserving hearing function (Myrseth et al. 2007). 
Radiosurgery can be performed by Gamma Knife, 
LINAC, or Proton-Radiotherapy, but Gamma Knife is the most 
widely used method for stereotactic radiosurgery for VS. 
Tumor control 
Rates of total removal of VS differ widely in the 
literature; however, it has been reported that in experienced 
hands, total removal is possible in 80–99% of cases (Gormley 
et al. 1997; Irving et al. 1998; Lanman et al. 1999; Sampath et 
al. 2000; Samii et al. 2006).  
The ability to completely remove VS depends on the 
consistency of the tumor and the presence of an arachnoid 
plane between the tumor and the brain. Total tumor removal is 
possible by dissecting the neurovascular structures from the 
false capsule of the tumor (Samii et al. 2006). 
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In cases of difficult dissection, a thin layer of tumor 
could be left attached to one or more cranial nerves in order to 
preserve their function (Kemink et al. 1991; Kameyama et al. 
1996; Bloch et al. 2004; Park et al. 2006; Seol et al. 2006; 
Freeman et al. 2007). 
 The residual tumor should be reduced in size as much 
as possible in order to minimize the rate of regrowth (Hwang et 
al. 2002; Bloch et al. 2004; Sughrue et al. 2011). 
Regrowth after subtotal removal of VS depends mainly 
on the vascularity and on the cellularity of the residual tumor. 
Tumor consistency may also play an important role, as cystic 
VSs may exhibit more rapid regrowth than solid tumors 
(Hwang et al. 2002). 
Bloch et al. (2004) followed 52 VS patients after near-
total (remnant ≤25 mm2 or ≤2 mm thick) and partial (any larger 
remnant) resections. The tumor recurrence rate was 3% after 
near-total resection and 32% after partial resection. 
 Sughrue et al. (2011) performed a study on 772 patients 
who underwent VS surgery during a 25-year period and were 
prospectively followed for many years postoperatively. They 
concluded that long-term rates of tumor control do not differ 
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between patients who undergo gross-total resection and those 
in whom a small amount of tumor is left behind.  
In the present series, total tumor removal was possible 
in 97.8% of the cases, and subtotal removal in 2.2% of the 
cases (n = 6). After a follow-up period ranging between 6 and 
74 months, tumor recurrence occurred only in one case (0.37% 
of the cases). The follow-up period in the cases of subtotal 
removal ranged between 15 and 74 months.  
Some tumor regrowth may occur during the early 
period following radiosurgery for VS, usually between 6 and 
24 months after radiation. This initial tumor expansion may be 
transient and the tumor may in fact decrease in size after the 
initial expansion. In large tumors, however, the initial 
expansion may cause compression-related symptoms and 
require surgical treatment (Fukouka et al. 2009).   
In the present series, tumor expansion occurred in 148 
patients (34.7%) six months after radiosurgery. Further follow-
up showed that tumor expansion was transient in 105 patients 
(24.5%) and these tumors eventually decreased in size from 
their maximum peaks at 8-24 months after the initial 
expansion. However, tumor expansion resulted in clinical 
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deterioration in three patients (0.7%), who required the 
insertion of VPS after developing hydrocephalus. 
The results following radiosurgery for VS are very 
unevenly described in the literature, including tumor growth 
less than or equal to 2 mm, no visible/measurable change, and 
further surgery required, among others (Bassim et al. 2010). 
Van Eck and Horstmann (2005) introduced two categories of 
tumor control after Gamma Knife radiosurgery for VS: "MRI-
based tumor control" when no increase, or increase of less than 
10% of the initial tumor volume was observed at follow-up, 
and "clinical tumor control" when clinical symptoms did not 
progress, and no further treatment was necessary. They 
reported that after a mean follow-up duration of 22 months, the 
magnetic resonance imaging–based tumor control rate was 
87%, while the clinical control rate was 97.5%. 
Nevertheless, more data are needed regarding long-term 
rates of tumor control after radiosurgery; especially for cases in 
which the marginal radiation dose was reduced in order to 
avoid cranial nerve complications. It has been documented that 
delayed tumor growth may occur even in cases where the 
tumor remained stable for 3 years after treatment (Roche et al., 
2008). In addition to that, long term follow up after 
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radiosurgery may allow the evaluation of serious side effects 
and functional outcome.  
In the present series, the follow-up period in the 
radiosurgery group ranged between 7 and 144 months, with a 
mean follow-up time of 42.4 months. Tumor control at the last 
follow-up showed tumor shrinkage in 71.9%, stable tumor in 
14.5%, and tumor expansion in 13.6% of the cases. On the 
other hand, long-term follow-up (at least 2 years after 
treatment) in our series revealed tumor shrinkage in 74.6%, 
stable tumor in 12.4%, and tumor expansion in 13% of the 
cases. 
Facial nerve Function 
It has been reported that anatomical preservation of the 
facial nerve is achieved in 93-99% of VS surgeries (Ojemann 
1993; Sekhar et al. 1996; Gormley et al. 1997; Samii and 
Matthies 1997a; Sampath et al. 1997; Lanman et al. 1999; 
Samii et al. 2006). 
Although transient deterioration of facial nerve function 
usually occurs after surgery, gradual recovery usually follows 
during the first 3 to 6 months postoperatively. Good 
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postoperative facial function (HB grade I or II) is achieved in 
52 to 93% of cases (Samii et al. 2006). 
The main predictor of facial nerve preservation after 
surgery is tumor size (Briggs et al. 2000; Jung et al. 2000; 
Staecker et al. 2000; Wiet et al. 2001). Other predictors include 
tumor extension, cystic tumor consistency, previous surgery or 
radiosurgery, and the surgeon’s operative experience (Samii et 
al. 2006). 
The rate of facial nerve palsy after radiosurgery for VS 
has dramatically decreased following improvement of dose 
planning and tumor imaging, which made smaller peripheral 
doses (10-14 Gy) possible (Régis et al. 2002). Yang et al. 
(2009b) conducted a review of 23 published studies that 
analyzed facial nerve outcome following radiosurgery for VS; 
they reported facial nerve preservation rate (HB grade I or II) 
of 96.2%.  
In the present series, we found a significant correlation 
between facial function at the last follow-up and tumor 
extension in the surgery group; however, in the radiosurgery 
group, facial function preservation was not significantly 
influenced by tumor extension, probably because the radiation 
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dose at the tumor margin was kept constant across all cases, 
irrespective of size.  
Previous studies comparing surgical and radiosurgical 
treatment of VS showed facial nerve function preservation (HB 
grade I or II) of 60-83% in surgery patients  and 91-100% in 
radiosurgery patients (Pollock et al. 1995, Karpinos et al. 2002, 
Régis et al. 2002, Myrseth et al. 2005, Pollock et al. 2006, 
Myrseth et al. 2009).  
In our series, facial function was preserved in 93.3% 
and 97.1% in the surgery and radiosurgery groups, 
respectively. In addition, facial function preservation rates 
were comparable between both groups for class T1 
(preservation rate 100% and 98.3% in the surgery and 
radiosurgery groups, respectively), class T2 (preservation rate 
97.1% and 98.5% in the surgery and radiosurgery groups, 
respectively) and class T3 tumors (preservation rate 97.1% and 
98.2% in the surgery and radiosurgery groups, respectively). 
Hearing preservation 
The rate of hearing preservation following surgery for 
VS ranges from 14 to 80% (Cohen 1993; Irving 1998; Koos et 
al. 1998). The most significant factors predicting hearing 
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preservation are tumor size and extension, and preoperative 
hearing level. 
Some authors have suggested that hearing preservation 
surgery should be undertaken only for small or medium-sized 
VSs (Slattery et al. 1997; Brackmann et al. 2000; Briggs et al. 
2000; Holsinger et al. 2000; Yates et al. 2003).  
Hearing preservation may be possible even with large 
VS. Hearing preservation rates of 9.1 to 50% have been 
reported for tumors > 3 cm (Fischer 1992; Yokoh et al. 1993; 
Cohen 1992; Fahlbuch et al. 1998; Iwai et al. 2003; Yamakami 
et al. 2004; Raftopoulos et al. 2005; Di Maio et al. 2005) and 
22.2 to 56.3% for tumors > 2 cm (Frerebeau et al. 1987; 
Gormley 1997; Wanibuchi et al. 2009). Samii et al. (2006) 
reported hearing preservation rates of 29 and 27% for T4a and 
T4b tumors, respectively. 
We believe it is best to aim for hearing preservation in 
all VS surgeries by utilizing continuous auditory evoked 
potential (AEP) monitoring. In our series, functional hearing 
was preserved in 58.8% of cases having serviceable hearing 
before surgery, and a significant correlation was found between 
hearing preservation and tumor extension. It is important to 
mention that the rate of hearing preservation was 26.3% in 
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cases of class T4 tumors, which suggests that hearing 
preservation should be a goal even in surgeries for large 
tumors. 
In a meta-analysis evaluating hearing results after 
radiosurgery for VS, hearing preservation was reported for 
57% of cases. It was also found that hearing preservation was 
significantly better in cases treated with a <12.5 Gy marginal 
radiation dose. No other factors (like tumor volume or patient 
age) were found to have a significant influence on hearing 
preservation (Yang et al. 2009). 
The results of previous studies comparing surgical and 
radiosurgical treatment of VS showed hearing preservation of 
0-40% in the surgery group and 32-75% in the radiosurgery 
group (Pollock et al. 1995; Karpinos et al. 2002; Régis et al. 
2002; Myrseth et al. 2005; Myrseth et al. 2009). However, it 
must be noted that these studies used different surgical 
approaches (including the translabyrinthine approach), and 
some of them did not use intraoperative neurophysiological 
monitoring (Régis et al. 2002; Myrseth et al. 2005; Myrseth et 
al. 2009).  
 In the radiosurgery group reported here, hearing was 
preserved in 65.7% of cases having serviceable hearing before 
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treatment, and, in contrast to what had been reported 
previously, it was also found to be significantly affected by 
tumor extension. 
Hearing preservation was found to be significantly 
better in the radiosurgery group (P value = 0.001, Mann-
Whitney). When we stratified the tumors by size, we observed 
that hearing preservation rates were not significantly different 
for small tumors; for class T1 tumors (preservation rate 86.7% 
and 73.5% in the surgery and radiosurgery groups, 
respectively), for class T2 tumors (preservation rate 61.8% and 
55.7% in the surgery and radiosurgery groups, respectively), 
and for class T3 tumors (preservation rate 60.9% and 70.3% in 
the surgery and radiosurgery groups, respectively). However 
for class T4 tumors, hearing preservation was better in 
radiosurgery group (preservation rate 26.3% and 69.6% in the 
surgery and radiosurgery groups, respectively). 
Other symptoms 
Results for the improvement of tinnitus, vertigo and 
imbalance after microsurgery and radiosurgery for VS vary 
widely in the literature. In a comparative study, Myrseth et al. 
(2009) found no significant difference between surgery and 
radiosurgery on tinnitus and vertigo visual analog scale scores 
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or balance platform tests. In another study, Pollock et al. 
(2006) compared microsurgery and radiosurgery on the 
Dizziness Handicap Inventory, a tinnitus survey, and a 
headache survey within 3 months of treatment and yearly. The 
results showed lower mean Dizziness Handicap Inventory 
scores in the radiosurgery group.  The results of another 
comparative study showed worsening of tinnitus in 26.5% of 
irradiated cases; however tinnitus remained unchanged in 
94.1% of cases in the microsurgery group (Karpinos et al. 
2000).  The same study reported no significant difference in 
experiencing worsened imbalance between the two groups 
(23.5% for radiosurgery vs. 22.4% for microsurgery, p= 0.932). 
Other authors have reported that patients who present with 
imbalance do poorly with radiation treatment and are better 
served by surgical intervention ( Coelho et al. 2008; Bassim et 
al. 2010). Lunsford et al. (2005) reported that tinnitus is usually 
unchanged after Gamma Knife radiosurgery for VS, with only 
infrequent cases of exacerbation. 
 In the surgery group of the present series, most of the 
patients who had dizziness or tinnitus prior to treatment 
improved completely or partially following surgery. This was 
not observed in the radiosurgery group, however, as dizziness 
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and tinnitus improved in 46.6% and 22.7% of patients, 
respectively. The results suggest that surgical treatment seemed 
to be a better option for patients suffering from tinnitus, 
dizziness, or trigeminal dysfunction before treatment, as it 
resulted in the significant improvement of these symptoms (P 
value < 0.0001, < 0.0001, = 0.036, respectively, Mann-
Whitney). 
 New trigeminal nerve dysfunction following 
radiosurgery has been shown to develop in 2-16% of cases, and 
this seems to depend largely on the radiation dose used 
(Rutherford and King 2005; Sughrue et al. 2009). Fukouka et 
al. (2009) reported that when trigeminal pain developed after 
radiosurgery, it was usually transient, while numbness was 
usually permanent. 
 In the present series, new trigeminal nerve dysfunction 
developed in 3.3% of cases in the radiosurgery group, and 
1.9% of cases developed trigeminal neuralgia. On the other 
hand, 2.5% of cases in the surgery group developed trigeminal 
nerve dysfunction postoperatively. 
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Complications 
Possible complications of microsurgery include CSF 
leakage 3-13% (Fischer et al. 1992; Glasscock et al. 1987), 
postoperative hemorrhage in 2.2% (Samii and Matthies 1997c), 
meningitis in 0.8- 2.5% (Ebersold et al. 1992; Wiegand and 
Fickel 1989), lower cranial nerve deficit in 0.5- 5.5% (Samii 
and Matthies 1997c) and hydrocephalus in 1-3% (Samii and 
Matthies 1997c). In the microsurgery group in the present 
series, 8.9% of cases developed CSF rhinorrhea and the 
leakage stoppe d in most cases after application of lumbar 
drainage; 1.5% of the operated cases developed 
hydrocephalous, and there were no cases of meningitis or 
postoperative hemorrhage requiring surgery. 
 Lee et al. (2010) suggested that adverse radiation 
effects may occur 6 to 18 months after Gamma Knife 
radiosurgery, and that these effects range widely, from mild 
effects responding to temporary corticosteroid therapy to 
severe effects requiring surgical treatment. They also claim that 
lower marginal doses around 12 Gy are associated with a low 
incidence of adverse radiation effects. The rate of 
hydrocephalus requiring intervention post-radiosurgery varied 
widely in the literature, ranging from 1 to 13% (Rutherford and 
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King 2005). In the present series, five patients (1.2%) 
developed hydrocephalus after radiosurgery and were treated 
by VPS insertion. The most common complication after 
radiosurgery was facial spasm, which occurred in 3.7% of 
cases. Another 1.9% developed trigeminal neuralgia. 
 Twelve cases of radiosurgery-associated malignant 
tumors have been reported so far worldwide (Schmitt et al. 
2011). Follow-up should be conducted 5-20 years following 
radiation in order to detect any radiation-associated tumors that 
may develop. Death may result from the possible 
complications associated with microsurgery, however, 
mortality rates are very low; a recent hospital-based study 
described 2,643 VS surgeries in 265 US Hospitals and reported 
a 3-month mortality rate of 0.5% (Barker et al. 2003). In our 
series, no patients developed radiosurgery-related malignancy; 
in addition, no patients developed serious postoperative 
complications or surgery-related mortality.  
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Conclusions 
 
 Tumor size is crucial in choosing treatment of 
vestibular schwannoma; several studies have compared 
microsurgery and radiosurgery for treatment of small and 
medium sized vestibular schwannoma. We compared 
retrospectively the results of two large centers treating 
vestibular schwannoma. The results in our work were divided 
according to tumor extension (according to Hannover tumor 
extension system), we compared both treatment groups then we 
performed separate analysis for small (Class T1 and T2) and 
large tumors (Class T3 and T4). Previously treated cases and 
cases on Neurofibromatosis type II (NF2) were excluded 
during our comparison. The items we depended upon during 
comparison included facial nerve function, hearing, tumor 
control, results of preoperative symptoms and complications. 
 The results showed that although radiosurgery was 
better in hearing and facial nerve preservation but the results 
were comparable in small tumors. So, radiosurgery offer 
advantage for better hearing and facial preservation only in 
large tumors. The results of tumor control were in favor of 
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microsurgery both in small and large tumors. Failure rate of 
radiosurgery require longer follow up especially after the 
application of smaller marginal radiation doses.   
From our results we can conclude the following: 
1- Microsurgery offer the opportunity for total or subtotal 
removal of large VS, and the long term recurrence rate 
is very low even in cases of incomplete removal. 
2- Surgeons experience and the use of intraoperative 
neurophysiological monitoring allow complete removal 
of most cases of VS with high rates of hearing and 
facial functional preservation. 
3- Adhering to the recent protocols of Gamma Knife 
radiosurgery by utilizing marginal dose of 13 Gy, high 
rates of hearing and facial function preservation could 
be achieved even in cases of large VS, and the long 
term results showed excellent tumor control rates. 
4- The results of tumor control following Gamma Knife 
radiosurgery showed no significant correlation to tumor 
extension. 
5- Radiosurgery gives better results than microsurgery 
regarding hearing and facial functional preservation 
 
77 
 
especially in large VS; however in cases of smaller 
(Class T1, T2 and T3) tumors, the results were 
comparable between surgery and radiosurgery.   
6- Patients presented with tinnitus and dizziness may 
benefit better from microsurgery.   
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Abstract 
Objective: 
 Treatment of vestibular Schwannomas, represent a matter of 
strong controversy, and to date no class I evidence can support 
the benefit of certain treatment modality over the others. 
Expectant treatment, microsurgery, and gamma knife 
radiosurgery represent the most important options to be 
considered. The main goal of the present study is to compare 
the functional outcome after gamma knife and surgical 
treatment in the long-term follow up.  
Patients and Methods: 
269 patients submitted to microsurgery and 427 patients treated 
with gamma knife in two different centers were followed up for 
16.4 ± 13.6 months and 42.4 ± 26.8 months respectively. 
Tumor volumetry based on serial MR images, facial nerve 
function according to the House-Brackman scale, hearing 
function according to the Gardner-Robertson scale, tinnitus, 
trigeminal symptoms, and dizziness were systematically 
analyzed and compared between both treatment modalities.  
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Results: 
Based on the normalized volumetry over time, surgery was 
more efficient than gamma knife on tumor control. While 
functional results regarding facial nerve and hearing 
preservation favored radiosurgery over surgery especially in 
large VS, the results were comparable in cases of smaller 
tumors (Class T1, T2 and T3). There was a relative advantage 
of surgery over radiosurgery for tinnitus, dizziness and facial 
hypoesthesia. 
Conclusion: 
Our results represent a further contribution to the field and 
offer evidence-based criteria to support the indication of one 
treatment modality according to patients’ expectations and 
professional activity. 
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Zusammenfassung 
 
Titel: Retrospektive Vergleichsstudie zur 
mikrochirurgischen und radiochirurgischen Behandlung 
von Vestibularisschannomen 
 
Ziel: Die Therapie von Vestibularisschwannomen gliedert sich 
weitestgehend in drei Teilbereiche: Mikrochirurgische 
Resektion des Tumors, strahlentherapeutische Behandlung oder 
sog. „Wait-Scan-Strategie“  womit eine Verlaufsbeobachtung 
des Tumorwachtums in festgelegten Intervallen gemeint ist. 
Eine evidenz-basierte Entscheidungshilfe im Sinne von 
Evidenz-Klasse-1 Studien, existiert in der medizinischen 
Literatur bis heute nicht. Das Hauptziel der vorliegenden 
Studie ist es daher, die funktionellen langfristigen Ergebnisse 
der strahlentherapeutischen Behandlung mit dem Gamma-
Knife und der mikrochirurgische Behandlung zu vergleichen. 
 
Patienten und Methoden: Die retrospektive Analyse der 
vorgelegten Studie beinhaltet 269 Patienten in der 
mikrochirurgische Gruppe und 427 Patienten in der 
radiochirurgischen Gruppe, mit medianen 
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Beobachtungszeiträumen von 16.4 ± 13.6 Monaten in der 
mikrochirurgischen Gruppe und 42.4 ± 26.8 Monaten in der 
radiochirurgischen Gruppe. Auswertung und statistische 
Evaluation von prä-therapeutischen Tumorvolumen 
(Hannover-Klassifikation) und deren Veränderung im 
Behandlungsverlauf, N. Fazialis-Funktion anhand der House-
Brackman-Skala, Hörfunktion anhand der Gardner-Robertson-
Skala, Beurteilung eines persistierenden Tinnitus, Störungen 
der Sensibilität im Gesicht (N.trigeminus Affektion), sowie 
persistierende Schwindel-Symtomatik wurden restrospektiv 
analysiert.  
 
Ergebnisse: Es zeigte sich im Langzeitsverlauf der 
Tumorvolumetriebestimmung besser Ergebnisse nach 
mikrochirurgischer Behandlung.  Die radiochirurgische 
Behandlung  war bezogen auf den funktionellen Erhalt der N. 
fazialis sowie des Erhalt des auditorischen Systems 
insbesondere bei grösseren Tumoren der mikrochirurgischen 
Resektion űberlegen, jedoch gilt dies nicht fűr kleine Tumore 
(Klasse T1, T2 und T3). Post-therapeutischer Tinnitus, 
Schwindelsymptomatik, sowie Beinträchtigung der N. 
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trigeminus Funktion zeigten mit mikrochirurgischer 
Behandlung bessere Endergebnisse.     
 
Schlussfolgerungen: Die Ergebnisse der vorgelegten Studie 
stellen einen weiteren nűtzlichen evidenz-basierten Beitrag zur 
Wahl der geeigneten Behandlungsmethode bei Patienten mit 
Vestibularisschwannomen dar. 
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